Redx Pharma
Redx is a UK biotechnology Group whose shares are traded on AIM [AIM:REDX]. Redx is focused on creating and developing first-in-class, or potentially best-in-class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.
Sector
Biopharmaceuticals
Strategies
Crossover
Status
Live
Website
www.redxpharma.com
Related News
Redx confirms changes to Board composition
Jazz Pharmaceuticals enters definitive agreement with Redx Pharma to acquire global rights to KRAS Inhibitor Program
Redx nominates GI-targeted ROCK Inhibitor, RXC008, as clinical development candidate
Redx Pharma plc Placing to raise c.£25.5 million and Open Offer to raise up to £2.2 million and Conversion of loan notes
Redx Pharma announces appointment of leading oncology drug developer, Dr Jane Robertson, as Chief Medical Officer
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.